[October 23, 2014] |
|
Pfizer Wins SUTENT® Patent Case In Delaware District Court
NEW YORK --(Business Wire)--
Pfizer Inc. announced today that the U.S. District Court for the
District of Delaware upheld its basic patent and the L-malate salt
patent covering SUTENT® (sunitinib malate) capsules. This decision,
which is subject to appeal, affirms Pfizer's right to exclusively
provide sunitinib malate as SUTENT to patients through the term of the
patent, which expires in 2021.
"The Court's decision acknowledges the validity and nfringement of our
patents and affirms the value of SUTENT, a standard of care in the
treatment of advanced renal cell carcinoma," said Douglas M. Lankler,
executive vice president and general counsel for Pfizer. "Defending our
intellectual property is crucial to our ability to discover and develop
innovative new medicines, which is at the very core of what we do."
Pfizer filed suit in June 2010 after Mylan Pharmaceuticals Inc. applied
to the U.S. Food and Drug Administration (FDA) to market a generic
version of SUTENT prior to the expiration of the patents covering
sunitinib malate and its uses. After a four-day trial, the Court agreed
that Mylan infringed the valid patents covering SUTENT.
The patents at issue are U.S. Patent Nos.6,573,293 and 7,125,905.
[ Back To TMCnet.com's Homepage ]
|